Quantum BioPharma Says FDA Cleared IND Application For Lucid-MS In Multiple Sclerosis, Enabling Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Loading news article.

Quantum BioPharma Says FDA Cleared IND Application For Lucid-MS In Multiple Sclerosis, Enabling Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial | WAPE

Quantum BioPharma Says FDA Cleared IND Application For Lucid-MS In Multiple Sclerosis, Enabling Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Article summary

Related companies

Analyzed by WAPE AI.

Comments —